Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy.

@article{Yao2005PeroxisomePR,
  title={Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy.},
  author={Qiang Yao and Louise Nordfors and Jonas Axelsson and Olof Heimb{\"u}rger and Abdul Rashid Qureshi and Peter Barany and Bengt Lindholm and Fredrik L{\"o}nnqvist and Martin Schalling and Peter Stenvinkel},
  journal={Atherosclerosis},
  year={2005},
  volume={182 1},
  pages={105-11}
}
BACKGROUND Inflammation may contribute to the markedly increased cardiovascular morbidity and mortality in end-stage renal disease (ESRD). However, the prevalence of inflammation varies in different ESRD populations. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is an important nuclear signaling protein that may regulate inflammatory response, and recent studies have revealed genetic polymorphisms that have significant effect on PPAR-gamma signaling. The aim of this study was to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Complementary LC-MS/MS Proteomic Analysis of Uremic Plasma Proteins.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP • 2015

Similar Papers

Loading similar papers…